

2nd Annual International Congress

World Cancer Conference

Cancer Prevention, Diagnostics & Treatment

癌症的预防控制、病症诊断及临床治疗

20 – 22 November, 2008, Beijing International Hotel, China

2008年11月20-22日, 中国北京国际饭店

Distinguished VIP Speakers

Prof Huang Jie-fu, Vice Minister
Ministry of Public Health China
Distinguished Expert for Live Transplantation

Dr Kong Ling Zhi, Deputy Director
Ministry of Health Disease Control
& Prevention Bureau

特别VIP演讲嘉宾

黄洁夫教授
中华人民共和国卫生部副部长
著名肝移植专家

孔灵芝博士
中华人民共和国卫生部疾病预防控制局副局长

Keynote Presentations from:

Prof He Jie, Chief of Thoracic Surgical Oncology, Vice President, Cancer Institute & Hospital, Chinese Academy of Medical Sciences

Prof David Khayat, Chief of Medical Oncology, Pitié-Salpêtrière Hospital & former President, French National Cancer Institute

Prof Nagahiro Saijo, President, International Association for Study of Lung Cancer & President, Japanese Society of Medical Oncology & Deputy Director, National Cancer Center Hospital East, Japan

Prof Mario Dicato, Hematologist-Oncologist & Chairman, Centre Hospitalier de Luxembourg

Prof Mohandas Mallath, Head of Dept. Digestive Diseases & Clinical Nutrition, Tata Memorial Hospital, Dean-Academic, Tata Memorial Centre, India

Prof John Milburn Jessup, Chief of Diagnostics Evaluation Branch, Cancer Diagnosis Program, DCTD, National Cancer Institute, USA

主题演讲人:

赫捷教授, 中国医学科学院肿瘤医院肿瘤研究所副院长, 肺癌中心主任

David Khayat教授, 法国萨伯特慈善医院(Pitié-Salpêtrière Hospital)肿瘤科主任; 法国国家癌症研究中心前任主席

Nagahiro Saijo教授, 日本千叶市国立癌症医院副院长, 国际肺癌协会主席, 日本内科肿瘤学会主席

Mario Dicato教授, 卢森堡公国癌症研究中心主席, 血液肿瘤专科医师

Mohandas Mallath教授, 印度塔塔纪念医院消化及临床营养科主任, 塔塔癌症研究中心学术院长

John Milburn Jessup教授, 美国国家癌症研究所癌症治疗与诊断中心诊断项目审核部主任

New in 2008:

- Updates on cancer epidemic & control strategy in Asia & China
- New approaches and strategies to diagnose and treat cancer
- Hear from clinical practitioners to understand current status & future trends for cancer therapy
- Learn from international experts to improve patient life quality with supportive care
- Focus on clinical research & evaluate technical developments in exploratory medicine

2008年会议关注主题

- 亚洲肿瘤病症流行趋势与政府预防控制计划第一手信息跟进
- 癌症治疗与生物学诊断的最新研究和实践
- 聆听来自临床实践者经验分享, 了解癌症疗法的现状与发展应用动向
- 留心国际专家最新研究, 运用支持治疗改善病患生活境遇
- 关注临床研究, 总结获取最新探索性抗癌药物的研究方法

www.ibcchina.com.cn/worldcancer

Approved By 批准单位:



Supporting association



Organised by 主办方:



Presented by 运作代表机构:



Registration
Hotline:
+86 (21) 2326 3680



World Cancer Conference

国际肿瘤大会

Cancer already kills more people worldwide than AIDS, tuberculosis and malaria combined.

Asia's prevalence of cancer deaths may climb 45% to 163 per 100,000 people by 2030, from about 112 per 100,000 in 2005. At that rate it would overtake the Americas, where cancer-related mortalities are expected to rise to 156 per 100,000 from 136 over the same period. Europe, which has the highest prevalence at 215 per 100,000, may increase by 9% to 234 per 100,000. In China, the cancer rate was close to that of the US, Britain and France, which is much higher than its Asian neighbours including Japan, India and Thailand. About 80% of cancer patients perished from common cancers of the lungs, liver and stomach.

Related spending on prevention and treatment is increasing rapidly, presenting a critical challenge for public healthcare system. With support from the Ministry of Public Health China, the World Cancer Conference (WCC) was developed to bring international cancer expertise to Asia for top level knowledge exchange in the region.

On behalf of the organizers, Informa Healthcare & PMPH, we sincerely welcome cancer researchers, clinical doctors and medical professionals to this exciting meeting, to bring the latest medical science and research, understand new technologies in cancer treatment and improve cancer care in China & beyond.

We looking forward to welcoming you to Beijing in November.

Who attended World Cancer Conference 2007:

Researchers, Professors & Clinical Doctors From:

Cancer Institute(Hospital), Chinese Academy of Medical Science • Beijing Stomatological Hospital • Guangdong Provincial People's Hospital • Fudan University Cancer Hospital, China • Peking Union Medical College • Beijing Ludaopei Hospital • Sun Yat-Sen University, China • Guangzhou Changxing Hospital • M.D Andersen Cancer Center, USA • Children's Medical Research Institute, Australia • Kyung Hee University, Korea • GAZIANTEP University, Turkey • National University of Singapore • National Chung Hsing University, Taiwan • Nagoya City University, Japan etc...

Industry Professionals & Scientists From:

AstraZeneca • Roche • Merck Sharp & Dohme • Novo Nordisk • IMS Health Asia • TTY BIOPHARMA • HuaDong Medicine • Hengrui Pharma • Medigreen Biotechnology • Egret Pharma • Edding Pharma • Asia Pacific Pharmaceutical Holding • Albany Molecular Centre • BioVeda • Beijing Honghui Meditech etc...

Sponsorship and Exhibition Opportunities

IBC has a consistent reputation in gathering senior professionals & decision makers from the healthcare industry for knowledge sharing & networking. Product & service exhibitions are also a key part of our program. World Cancer Conference provides your business with rewarding market positioning and unlimited new business development opportunities. Maximise your presence with a number of lead-generating, networking, and branding packages including:

- Conference sponsor
- Technology tutorial
- Networking reception
- Exhibition stand
- Professional Workshops

For further information, please email
linda.wan@ibcchina.com.cn

Media Partners



Official Journals



在会议上展示您的最新研究成果!

您希望与同行以及医疗行业领袖分享您的研究成果吗?
论文公开展示环节为您提供一个绝佳的机会在会议和展览上展示您的最新科学研究项目及成果,以供同行研讨。

提交您的文章摘要

当您注册成为大会参会代表之后,您便有机会在会场张贴关于您最新科学研究内容的海报。作为申请,请您提交我们200字左右的英文摘要,并列出主要作者,包括所有联系信息(机构名称、邮递地址、电子邮件、电话、传真、海报、标题、附加作者等),并发送至大会秘书处何麒先生,电子邮件地址为kelvin.ho@ibcchina.com.cn。研究论文展示文章提交的截止日期为2008年10月12日。文章被大会接受后将收取US\$100/CNY700作为海报栏的费用。

Present A Poster At This Event!

Would you like to share your research with your peers and the key industry leaders in healthcare?

Poster sessions offer you a unique opportunity to have your scientific research projects displayed at this conference and exhibition, to be reviewed by your peers.

Submitting Your Abstract

You must be registered as a delegate to present a poster. To apply, please submit your abstract of 200 words or less, written in English, listing the principal author and full contact details (organisation, mailing address, E-mail, phone, fax, poster, title, additional authors) to Kelvin Ho at kelvin.ho@ibcchina.com.cn

Last date for submission of posters is 12 October 2008. In order to secure the Poster Board, a fee of US\$100/CNY700 will be required.

REGISTER Today! Call our customer service today to reserve your place at this event Tel +86 21 2326 3680 or email register@ibcchina.com.cn



Cancer Prevention, Diagnosis & Treatment 癌症的预防控制、诊断及治疗

Day One | Thursday 20th November, 2008

08:00 Morning coffee and registration

08:30 Welcome from organiser

08:35 **Chairman Opening remarks**

08:45 **Opening address from Guest of Honour**

Prof Huang Jie-Fu, *Vice Minister*, Ministry of Public Health, China

CANCER CONTROL & TREATMENT DEVELOPMENTS

09:00 **Organ transplant- development as a novel treatment for liver cancer**

- Overview of liver transplants in Asia: past experience, current status & future developments
- Combining radiation, chemotherapy with liver transplant to improve survival rates
- Pre-surgery evaluation: key factors for the decision making process
- LDLT for liver cancer treatment in China

Prof Huang Jie-Fu, *Vice Minister*, Ministry of Public Health, China

09:35 **Overview of cancer disease control & prevention initiatives in China**

- Epidemiology overview of cancer disease in China
- Government initiatives for cancer prevention, diagnosis & treatment
- Public private partnership practice for cancer control in China

Kong Ling Zhi, *Deputy Director of Disease Control Department*, Ministry of Public Health, China

10:10 **International perspective: Cancer Control in France & the War on Cancer Plan 2003-2008**

Prof David Khayat, *Head of Medical Oncology*, Salpetriere Hospital & *Former President*, French National Cancer Institute

10:45 Morning refreshment & poster/exhibition viewing time

EPIDEMIOLOGY & PREVENTION

11:15 **Epidemiology and prevention of hepatitis associated hepatocellular carcinoma – a worldwide translational approach**

A meta-analysis on the seroprevalence of HBsAg and anti-HCV antibodies in 27 881 hepatocellular carcinomas from 90 studies confirmed wide international variations. A predominance of HBsAg was found in hepatocellular carcinomas from most Asian, African and Latin American countries, but anti-HCV predominated in Europe, North America, Japan, Pakistan, Mongolia, and Egypt. Anti-HCV was found more often than HBsAg in Europe and the United States. 25 years after having been licensed, HBV vaccination programs are now carried out in 158 countries, but they have yet to reach many high-risk populations in sub-Saharan Africa and Asia. In the absence of a vaccine, the prevention of HCV infection requires an integrated strategy (ie, screening of blood donations, safe injection practices and avoidance of unnecessary injections).

Syed Ahsan Raza, MD MSc, *Senior Instructor*, Research Department of Surgery, The Aga Khan University

11:50 **The modulating role 5-LOX in the carcinogenic action of cigarette smoke and its active component in colon cancer**

Substantial evidence indicates that cigarette smoke exposure is a risk factor for colorectal cancer. We investigated the modulating role of cigarette smoke and its active component NNK, in 5-LOX expression and expression of 5-LOX in SW1116 colon cancer cells. It also promoted 5-LOX DNA de-methylation. NNK stimulated colon cancer cell proliferation, enhanced $\alpha 7$ -nAChR mRNA level, NF- κ B DNA binding activity, 5-LOX and COX-2 expression. Inhibitors of COX-2 and 5-LOX inhibited tumor growth in nude mice. The present study demonstrates the central role of 5-LOX in the carcinogenic action of cigarette smoke and NNK on colon cancer.

Prof Cho Chi Hin, *Professor of Pharmacology & Chairman*, Department of Pharmacology, Faculty of Medicine, The Chinese University of Hong Kong

12:25 **TECHNOLOGY TUTORIAL:**

Technology and product providers will provide interactive educational tutorials which address the benefit of their technology or product in the field of cancer diagnostics, prognosis analysis & treatment development. If you would like to host a tutorial, please contact linda.wan@ibcchina.com.cn

12:45 Luncheon & poster/exhibition viewing time

DISEASE MANAGEMENT & TREATMENT INNOVATION I

14:00 **Advances in Surgical Management of Esophageal Cancer**

Esophageal Cancer is one of the most common cancer types in China and fourth killer of cancer in Chinese population. Even there are quite a lot of new drugs & therapies developed in this area, surgical operation is still the most mature treatment for esophageal carcinoma. In the session, Dr He Jie will share you his research & insights in surgical management of this common disease in Asia.

Prof He Jie, *Chief of Thoracic Surgical Oncology, Vice President*, Cancer Institute & Hospital, Chinese Academy of Medical Sciences

14:35 **Treatment for advanced non-small cell lung cancer**

While there have been advances in the treatment of lung cancer, they have been marginal with recent advances in the chemotherapy and molecularly targeted treatment of breast, colorectal and genitourinary cancers. Lung cancer is extremely difficult to treat, obtain positive results and develop new standard treatments. The results of clinical trials on gefitinib and erlotinib suggest that the evaluation of molecular target drugs is quite difficult in unselected patient population and may be different from cytotoxic drugs. We need to identify specific molecular biomarkers for each drug. In view of global studies, it will be essential to obtain more significant results by sophisticated clinical trials in selected patient populations and contribute to improving the treatment outcome of lung cancer patients.

Prof Nagahiro Saijo, M.D., Ph.D, *President*, International Association for Study of Lung Cancer; *President*, Japanese Society of Medical Oncology & *Deputy Director*, National Cancer Center Hospital East, Japan

15:10 **Updates and future development of neoadjuvant chemotherapy for breast cancer**

Prof Wu Shi Kai, *Deputy Director*, Department of Breast Cancer, 307 Hospital, Academy of Military Medicine Sciences, China

15:45 Afternoon refreshment & poster/exhibition viewing time

CLINICAL TRIALS IN CHINA

16:15 **Phase III/IV clinical trial in China for better treatment**

- Current regulation guidelines for phase III/IV trial patient recruitment
- Ethical issues in trial design & operation process
- Experiences from Western countries

16:50 **Clinical challenges of cancer drug combinations**

- Assessing combination therapies
- Obtaining accurate dose response information
- Calculating maximum tolerated dosage and biological effective dosage
- Lessons learned from real-life experiences

17:25 Chairman's remarks & close of conference day 1

17:30 Networking cocktail reception

REGISTER Today! Call our customer service today to reserve your place

gnostics & Treatment 症诊断及临床治疗

Day Two | Friday 21st November, 2008

08:30 Morning coffee & tea

DISEASE MANAGEMENT & TREATMENT INNOVATION II

09:00 **Progress on advanced colorectal cancer**

Prof David Khayat, *Head of Medical Oncology*, Salpetriere Hospital & *Former President*, French National Cancer Institute

09:35 **Clinical practice advance for liver cancer management**

Prof Zhang Yangde, *President*, National Hepatobiliary & Enteric Surgery Research Center, Ministry of Health

10:10 **Treatment development for gastric cancer**

Prof Alex Y. Chang, *Chief Executive Officer & Medical Director*, John Hopkins Singapore International Medical Centre (*Invited*)

10:45 Morning refreshment & poster/exhibition viewing time

CANCER BIOMARKERS & DIAGNOSTICS

11:15 **Development and implementation of assays in cancer care**

Although increasingly important for targeted and personalized therapies in the cancer patient, the development and validation of useful biomarkers is often stopped by inadequate assay development. The Cancer Diagnosis Program of the National Cancer Institute has identified multiple needs for assay development that include: specimen acquisition, access to standards and reagents, education on assay development, support for improving assay performance and validation for clinical use. This session will focus on making assays robust and validated for predicting response to therapy and monitoring molecular recurrence.

Dr J. Milburn Jessup, *Chief of Diagnostics Evaluation Branch*, Cancer Diagnosis Program, DCTD, National Cancer Institute, USA

11:50 **Circulating tumor cells (CTC) as a prognostic and predictive indicator in advanced lung cancer patients**

Scientists have long believed that circulating tumor cells held a wealth of information. This study has shown that negative enrichment immunomagnetic-based technology plays a definitive role in predicting and judging prognosis of lung cancer patients. CTC will go a long way towards addressing an unmet need in the cancer field and could change the course of treatment for many critically ill patients.

Prof Zhou Xiao-Yun, *Department of Respiratory Diseases*, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences

12:25 **TECHNOLOGY TUTORIAL:**

Technology and product providers will provide interactive educational tutorials which address the benefit of their technology or product in the field of cancer diagnostics, prognosis analysis & treatment development. If you would like to host a tutorial, please contact linda.wan@ibcchina.com.cn

12:45 Luncheon & poster/exhibition viewing time

SUPPORTIVE CARE

14:00 **Erythropoietin, where do we stand now?**

- Controversies 2007-2008
- Epo- receptor determination on cancer cells: what do they imply? Induction of progression of the cancer clone?
- How to use erythropoietins in the clinic: advantages and risks

Dr Mario Dicato, *Hematologist-Oncologist*, Centre Hospitalier de Luxembourg

14:35 **Clinical nutrition support during cancer treatments**

Malnutrition is the commonest co-morbidity associated with cancer and a substantial proportion of cancer patients die from cachexia. Patients with cancer in the digestive tract, respiratory tract and head and neck regions are at greatest risk of developing malnutrition. Malnutrition suppresses immunity, delays tissue repair and promotes the loss of muscle mass and hypoproteinemia which results in increased morbidity, mortality, hospital stay and costs. As a result, intensive nutritional support was used to improve the immediate and long term outcomes of cancer treatment. The results of most randomized clinical trials have not been remarkable. Paradoxically, routine use of parenteral nutrition during cytotoxic therapies can result in net harm. Benefit has been demonstrated in preoperative parenteral nutrition in patients undergoing curative surgery for cancer of the upper gastrointestinal tract. In general, all cancer patients should be assessed for malnutrition at initial presentation. At the same time, it is essential that medical and paramedical oncology staff maintain an active interest in nutrition support to ensure maximal benefits from the intervention.

Prof Mohandas Mallath, *Head of Dept. Digestive Diseases & Clinical Nutrition*, Tata Memorial Hospital, & *Dean-Academic*, Tata Memorial Centre, India

15:10 Afternoon refreshment & poster/exhibition viewing time

ROUND TABLE DISCUSSION

15:40 **Emerging technologies & economic realities: can we afford the bill for modern cancer care?**

Over the past two decades, new technologies such as PET/CT, radiotherapy, mAbs & biological drugs bring us better hope for cancer treatment. However, the cost of cancer treatment has significantly increased. During this interactive roundtable debate, we will discuss how to implement best therapy to your patient with a cost effective plan.

16:15 Chairman's remarks & end of conference

TCM / Olympic Stadium / Cultural Evening | Saturday 22nd November, 2008

Site Tour to TCM Cancer Hospital

TCM is part of traditional medical technology development by ancient Chinese. Within thoughts of year development, it has established a unique philosophy & understanding of diseases. Currently, significant advances in research has been conducted in cancer management via TCMs.

The 3 hours tour will provide a preview of how TCM works in China as an alternative therapy for cancer patients.

Attendees will meet at the hotel lobby at 9am and return around 12noon.



Visit Beijing's "Bird's Nest" Stadium

Host venue of the recently conducted Olympics and spectacular, The "Bird's Nest" Stadium has become an instant icon of Beijing. View the surrounding area including the Water Cube and visit the stadium on this half day tour.

PMPH Celebrates! Cultural Evening

Join PMPH as it marks its 50th anniversary with an evening performance at Chang'an Theater. Featuring Beijing Opera and traditional Chinese art performance.

癌症研究与抗癌新药研发

星期四, 2008年11月20日

- 08:00 早间咖啡及参会人员报到
- 08:30 主办方致开幕词
- 08:35 **卫生部领导致辞**
黄洁夫教授, 中华人民共和国卫生部副部长,
- 08:45 大会主席致辞
- 大会主题演讲 - 癌症控制与疗法发展**
- 09:00 **肝脏移植在肝癌治疗的运用及指导意义**
 - 肝移植技术在亚洲发展的过去, 现在及未来
 - 通过针对性地对放疗和化疗病人实施肝移植, 增加病人的生存率
 - 移植手术前准备: 如何确认病人是否应该通过移植手术进行肝癌治疗
 - 成人间活体肝移植手术在中国的发展对于癌症治疗带来的影响**黄洁夫教授**, 中华人民共和国卫生部副部长
- 09:35 **癌症在中国的流行现状及政府疾病控制行动计划**
 - 癌症在中国的流行状况概述
 - 政府在癌症预防、诊断及治疗方面的采取的行动计划和措施
 - 中国癌症控制中的公共机构与私人企业合作**孔灵芝博士**, 中华人民共和国卫生部疾病预防控制局副局长
- 10:10 **法国癌症控制经验分享: 2003至2008的抗击之战**
David Khayat教授, 法国萨伯特慈善医院肿瘤内科主任; 法国国家癌症中心前主席
- 10:45 **上午咖啡以及海报/展览参观时间**
- 癌症的流行现状与预防**
- 11:15 **与肝炎相关的肝癌流行病学研究与预防监控 - IACR全球范围转化研究分享**
Syed Ahsan Raza教授, 巴基斯坦Aga Khan大学外科主任
- 11:50 **癌症预防与控烟 - 5脂氧合酶在吸烟致癌机制中的作用以及其对肠癌的影响研究**
曹之宪教授, 香港中文大学医学院药理学系主任
- 12:25 **技术宣讲: 如果您希望主持此项活动**
请联系 linda.wan@ibcchina.com.cn
- 12:45 午餐以及海报/展览参观时间
- 疾病管理及疗法创新 I**
- 14:00 **食道癌手术治疗进展及临床实践研究**
赫捷教授, 中国医学科学院肿瘤医院肿瘤医院研究所副院长, 肺癌中心主任
- 14:35 **晚期非小细胞肺癌的治疗发展**
Nagahiro Saijo教授, 日本内科肿瘤学会 (JSMO) 主席, 日本千叶市国立癌症医院副院长
- 15:10 **新辅助化疗对乳腺癌治疗的发展现状与前景预测**
吴世凯教授, 中国人民解放军307医院肿瘤内科副主任医师
- 15:45 下午咖啡以及海报/展览参观时间
- 肿瘤药物临床试验在中国**
- 16:15 **在中国引入三期/四期药物临床研究, 为病患提供更好的治疗方案**
 - 现有中国对于三期四期临床药物研究病人招募的指导规定
 - 临床实验设计及执行中的伦理问题管理
 - 西方国家对实验药物临床治疗运用的管理经验
- 16:50 **肿瘤多方案结合治疗中的临床试验管理**
 - 多方案结合治疗的评估
 - 获取准确的剂量及相关病人的反馈信息
 - 计算病人的最大耐受剂量及生物学有效剂量
 - 实践经验分享
- 17:25 大会第一天结束, 主席致辞
- 17:30 晚间鸡尾酒接待会

星期五 2008年11月21日

- 08:30 早间咖啡
- 疾病管理及疗法创新II**
- 09:00 **肠癌治疗的技术演进与发展**
David Khayat教授, 法国萨伯特慈善医院肿瘤内科主任; 法国国家癌症中心前主席
- 09:35 **肝癌临床治疗之我观**
张阳德教授, 国家卫生部肝胆肠外科研究中心主任
- 10:10 **胃癌临床治疗发展**
Alex Y. Chang教授, 约翰霍普金斯-新加坡国际医疗中心首席执行官兼医学主任 (特邀)
- 10:45 上午咖啡以及海报/展览参观时间
- 癌生物学标志物科学展及临床应用**
- 11:15 **癌症诊断及生物学标志物发展对于临床治疗的指导**
John Milburn Jessup教授, 美国国家癌症研究所癌症治疗与诊断中心诊断项目审核部主任
- 11:50 **以循环肿瘤细胞(CTC)作为晚期肺癌病人预后以及复发预测指标的临床研究**
周晓芸教授, 中国医学科学院癌症研究所·北京协和医院呼吸内科
- 12:25 **技术宣讲: 如果您希望主持此项活动**, 请联系 linda.wan@ibcchina.com.cn
- 12:45 午餐以及海报/展览参观时间
- 癌症支持治疗**
- 14:00 **促红细胞生成素: 我们应如何理性面对潜在的副作用?**
Mario Dicato教授, 血液肿瘤专科医师, 卢森堡癌症中心主席
- 14:35 **癌症治疗中对病患的临床营养支持**
Mohandas Mallath教授, 印度塔塔纪念医院消化及临床营养科主任, 塔塔癌症研究中心学术院长
- 15:10 下午咖啡以及海报/展览参观时间
- 全体互动圆桌讨论**
- 15:40 **新疗法与新技术的经济性分析: 我们是否有能力支付现代癌症疗法的昂贵医疗成本?**
过去20年间, 不断涌现的新技术诸如PET/CT影响诊断、放射疗法、单克隆抗体以及生物药物, 为人类带来了癌症治疗的新曙光。但是, 相关的医疗成本也在成倍增长。在本环节中, 我们将重点讨论如何为各种不同的癌症病患设计提供成本与疗效更为经济的治疗方案。
- 16:15 大会第二天结束, 主席致辞

中医之旅 / 奥林匹克国家体育场游览 / 文艺晚会活动 | 星期六 2008年11月22日

学术参观中医医院

中医中药是中国古代先民留下的传统医学技艺瑰宝。历经数千年的发展演绎, 中医针对各种病因病理, 已经建立了一整套独特的体系进行诊断和治疗。在癌症治疗方面, 目前也有大量的研究关注与中药对癌症病人的治疗作用。

通过本次为时约3小时的参观活动中, 我们将带领大家去窥探此项中华瑰宝的神奇魅力。

游览国家体育场“鸟巢”



国际体育场鸟巢因其独特的外观设计和作为奥运会主体育场馆的身份, 目前已经成为了北京的又一标志性建筑。在此次为期半天的游览中, 我们将带领您领略鸟巢及其周边的水立方等建筑奇迹。

中国人民卫生出版社社庆晚会活动



中国人民卫生出版社成立50周年社庆晚会活动将在长安大戏院举行。其间将有京剧表演等节目, 向各国来宾展现中国传统艺术的独特魅力。

请致电我们的客服热线预定您的席位! 电话: +86 21 2326 3680, 电子邮件: register@ibcchina.com.cn

If undelivered, please return to:



IBC ASIA (S) PTE LTD

Company No: 200108203N

No.1 Grange Road

#08-02 Orchard Building, Singapore 239693

Tel: (65) 6732 1970

Fax: (65) 6733 5087 / (65) 6736 4312

PRINTED MATTER
AIR MAIL

World Cancer Conference 国际肿瘤大会

HOTEL INFORMATION

Beijing International Hotel

9 Jianguomennei Dajie, Beijing, China

Zipcode: 100005

Tel: (86 -10) 65126688

Hotel room booking, pl contact:

Ms. Yang and Mr. Shen

pmph_2007@126.com

Tel: +86 10 67711608

Fax: +86 10 87713688

5 EASY WAYS TO REGISTER

China

✉ Mail the attached registration form with your cheque to IBC Conferences And Event Management Services (Shanghai) Co., Ltd
Room 3203, LT Square, 500 Chengdu Road North, Shanghai 200003

TEL : +86 21 2326 3680

FAX : +86 21 5375 0690

E-MAIL: register@ibcchina.com.cn

WEB: www.ibcchina.com.cn/worldcancer

Singapore

✉ Mail the attached registration form with your cheque to IBC Asia (S) Pte Ltd,
No. 1 Grange Road, #08-02, Orchard Building, Singapore 239693

CUSTOMER SERVICE TELEPHONE:
(65) 6514 3180 / (65) 6732 1970
FAX: (65) 6733 5087
(65) 6736 4312

E-MAIL: register@ibcasia.com.sg

PAYMENT

Payments by RMB

Account Name:

艾毕思会务服务(上海)有限公司

Account No. 720-031103-001

Beneficiary Bank: 汇丰银行(中国)

有限公司上海分行

Bank Address: No. 1000 Lujiazui Ring

Road, Pudong, Shanghai 200120

P. R. China

Payments by US\$

Payment by telegraphic transfer in US\$ must be made to:

IBC CONFERENCES AND EVENT
MANAGEMENT SERVICES (SHANGHAI)
CO., LTD.

A/C No: 001-396282-056

Beneficiary Bank: HSBC Bank (China)

Company Limited

Bank Address: No. 1000 Lujiazui Ring

Road, Pudong, Shanghai 200120

P. R. China

Swift Code: HSBCCHNS

IMPORTANT NOTE:

Please quote the name of the delegate and event title on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Conferences and Events Management (Shanghai) Co., Ltd. will not be responsible for any event re-scheduled or cancelled.

DATA PROTECTION

The personal information shown on this brochure, and / or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from, or made available to, external companies for marketing purposes. If you do not wish your details to be used for marketing purposes, please write to our Database Manager, IBC Asia (S) Pte Ltd.

GROUP BONUS
25% off for 3rd and subsequent delegates.
三人以上注册, 自第三人起注册可享受25%优惠
Discounts may not be combined

This label contains your priority booking code.
To expedite registration, please do not remove label.

If you have already received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were not available to IBC Asia (S) Pte Ltd for deduplication prior to mail drop.

RESERVE YOUR PLACE TODAY! 今天就预订您的位子吧!

☐ Yes! I/We will attend the WORLD CANCER CONFERENCE 20 - 22 November 2008, Beijing, China

☐ Yes! I/We will attend the WORLD CANCER CONFERENCE 20 - 21 November 2008, Beijing, China

1st delegate / 第一名代表

2nd delegate / 第二名代表

Name / 姓名: _____

Name / 姓名: _____

E-Mail / 电邮地址: _____

E-Mail / 电邮地址: _____

Job Title / 职位: _____

Job Title / 职位: _____

Mobile no / 手提电话: _____

Mobile no / 手提电话: _____

Department / 部门: _____

Department / 部门: _____

Company / 公司: _____

Address / 通讯地址: _____

Post Code / 邮编: _____

Country / 国家: _____

Tel / 电话: _____

Fax / 传真: _____

Name & Title of Approving Manager / 准予参会的上级姓名与职位: _____

Name & Title of Training Manager / 培训经理的姓名: _____

Main Business/Activity / 公司主要业务: _____

Please tick

☐ I am paying by bank transfer (copy attached) / 我通过银行转账付款(请见付款凭据复印件)

请在合适项目打勾

☐ Payment by Credit Card / 我通过信用卡付款 请 ☐ Amex 请 ☐ Visa 请 ☐ Mastercard 请 ☐ JCB

I cannot attend this event but / 我不能参加此次会议

☐ Please put me on your mailing list / 我仍希望收到其它相关会议的邀请函

☐ I would like to purchase conference documentation USD565/CNY4,000 per set / 我希望购买此次会议的资料 (USD565/CNY4,000)

Code: 80084 Eric

Please select the appropriate package	Early Bird Rate		Normal Discount Rate	
	Register & Pay before 24 October 2008 2008年10月24日前注册并付款		Register & Pay 24 October 2008 2008年10月24日后注册并付款	
Currencies 货币种类	USD	RMB	USD	RMB
For academics, hospitals outside China				
<input type="checkbox"/> 2 days conference only 两天会议注册	USD 995	CNY 6,965	USD 1,095	CNY 7,665
Fee per Delegate for International Companies 外资公司及跨国集团				
<input type="checkbox"/> 2 days conference only 两天会议注册	USD 1,495	CNY 10,465	USD 1,595	CNY 11,150
Optional Half / Full day tour (22 November)				
<input type="checkbox"/> Morning TCM Hospital / Birds Nest Stadium Tour / Cultural Evening			USD 100	CNY 700
<input type="checkbox"/> Morning TCM Hospital / Birds Nest Stadium Tour & Evening			USD 180	CNY 1,260

To Reserve a Posterboard (Space is limited) 预定大会论文布告板位置 ☐ USD\$100/CNY700

We recommend TT/Wire transfer for payment in US\$. For credit card payments, please note that US\$ equivalent may vary as the RMB rate will be charged

* Academy/Government rate is to full employees of government, universities & university-affiliated hospitals only

** All fees are inclusive of a 5.5% Sales Tax. Fee includes luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.

CANCELLATIONS / SUBSTITUTION

Cancellations received in writing 10 working days before the event will be entitled to a full refund less 10% administration fee. Thereafter, cancellations are not refundable. Participants may be substituted at any time.

REGISTER NOW! Fax back to +86 (21) 5375 0690